Arecor Therapeutics PLC Exercise of options, PDMR, Total Voting Rights (1835Q)
26 October 2021 - 2:25AM
UK Regulatory
TIDMAREC
RNS Number : 1835Q
Arecor Therapeutics PLC
25 October 2021
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
Exercise of options, PDMR dealing and Total Voting Rights
Cambridge, UK, 25 October 2021: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives , announces that it has issued and allotted
151,492 new Ordinary Shares of 1 pence each in the share capital of
the Company following an exercise of options on 25 October 2021 at
an exercise price of 1 pence per Ordinary Share. The options
exercised were part of the rollover of share options previously
granted under the historic Arecor Limited EMI Share Option Plan
2018 ("Option Rollover"). Details of the Option Rollover are set
out in the Company's Admission Document.
Included in the exercise of options were options over 123,336
ordinary shares held by Directors/PDMRs of the Company as detailed
in the table below:
Director/ PDMR Position Existing Number of Resultant Options
interest in Options over interest in remaining after
Ordinary Shares Ordinary Ordinary exercise
Shares Shares
exercised
David Gerring VP, Development 142,956 8,336 151,292 83,334
------------------- ------------------ ----------------- ----------------- ------------------
Chief Executive
Sarah Howell Officer 788,742 51,664 840,406 360,666
------------------- ------------------ ----------------- ----------------- ------------------
Chief Scientific
Jan Jezek Officer 396,138 8,336 404,474 163,334
------------------- ------------------ ----------------- ----------------- ------------------
VP, Clinical &
Regulatory
Fiona Lawrence Affairs 66,168 4,166 70,334 81,666
------------------- ------------------ ----------------- ----------------- ------------------
Chief Financial
Susan Lowther Officer 110,681 25,834 136,515 322,000
------------------- ------------------ ----------------- ----------------- ------------------
James VP, Business
MacDonald-Clink Development - 25,000 25,000 105,000
------------------- ------------------ ----------------- ----------------- ------------------
Admission
Following the above transactions, application has been made for
the 151,492 new Ordinary Shares to be admitted to trading on AIM
("Admission") and dealings are expected to commence on, or around,
29 October 2021. The new Ordinary Shares will rank pari passu with
the Company's existing Ordinary Shares.
The total number of Ordinary Shares in issue following Admission
will be 27,835,024. Accordingly, the figure of 27,835,024 may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in the Company under the
FCA's Disclosure and Transparency Rules.
For further information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited Tel: +44 (0) 20 7886 2500
(NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat (TM) platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
Details of the person discharging managerial responsibilities/person
closely associated
a) Name: a) David Gerring
b) Sarah Howell
c) Jan Jezek
d) Fiona Lawrence
e) Susan Lowther
f) James MacDonald-Clink
--------------------------------- -----------------------------------------
2. Reason for the notification
----------------------------------------------------------------------------
a) Position/status: a) VP, Development
b) Chief Executive Officer
c) Chief Scientific Officer
d) VP, Clinical & Regulatory
Affairs
e) Chief Financial Officer
f) VP, Business Development
--------------------------------- -----------------------------------------
b) Initial notification/Amendment: Initial notification
--------------------------------- -----------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name: Arecor Therapeutics PLC
--------------------------------- -----------------------------------------
b) LEI: 98450093D12I3A8DDD58
--------------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------
a) Description of the financial Ordinary shares of 1 pence
instrument, type of instrument: each
Identification code: GB00BMWLM973
--------------------------------- -----------------------------------------
b) Nature of the transaction: Exercise of options over ordinary
shares
--------------------------------- -----------------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
a) GBP0.01 a) 8,336
----------
b) GBP0.01 b) 51,664
----------
c) GBP0.01 c) 8,336
----------
d) GBP0.01 d) 4,166
----------
e) GBP0.01 e) 25,834
----------
f) GBP0.01 f) 25,000
----------
--------------------------------- -----------------------------------------
d) Aggregated information:
* Aggregated volume: 123,336
GBP0.01
* Price:
--------------------------------- -----------------------------------------
e) Date of the transaction: 25 October 2021
--------------------------------- -----------------------------------------
f) Place of the transaction: London Stock Exchange, AIM
Market (XLON)
--------------------------------- -----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBUBDGXDDDGBU
(END) Dow Jones Newswires
October 25, 2021 11:25 ET (15:25 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2023 to Apr 2024
